Dimethyl fumarate versus interferon for treatment of relapsing-remitting multiple Sclerosis

被引：0
|
作者：
Sattarnezhad, Neda [1 ]
Healy, Brian C. [1 ,2 ]
Baharnoori, Moogeh [1 ]
Diaz-Cruz, Camilo [1 ]
Stankiewicz, James [1 ]
Weiner, Howard L. [1 ]
Chitnis, Tanuja [1 ,3 ]
机构：
[1] Brigham & Womens Hosp, Partners MS Ctr, Boston, MA 02115 USA
[2] MGH Biostat Ctr, Boston, MA USA
[3] Massachusetts Gen Hosp, Pediat MS Ctr, Boston, MA 02114 USA
来源：
NEUROLOGY | 2017年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P6.381
引用
收藏
页数：3
相关论文
共 50 条
  • [41] The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada
    Su, Wenqing
    Kansal, Anuraag
    Vicente, Colin
    Deniz, Baris
    Sarda, Sujata
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (07) : 718 - 727
  • [42] Clinical evaluation of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis: efficacy, safety, patient experience and adherence
    Narapureddy, Bhavya
    Dubey, Divyanshu
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2019, 13 : 1655 - 1666
  • [43] Treatment patterns in the use of dimethyl fumarate in relapsing-remitting multiple sclerosis in Denmark A Danish nationwide cohort study
    Magyari, M.
    Buron, M.
    Joensen, H.
    Kopp, T. Iskov
    Rasmussen, P. V.
    Blinkenberg, M.
    Sorensen, P. S.
    Sellebjerg, F.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 518 - 519
  • [44] COST-MINIMIZATION ANALYSIS OF TERIFLUNOMIDE AND DIMETHYL FUMARATE FOR TREATMENT OF RELAPSING-REMITTING FORMS OF MULTIPLE SCLEROSIS IN ITALY
    Stanisic, S.
    Bergamaschi, R.
    Berto, P.
    Di Procolo, P.
    Marocco, A.
    Morawski, J.
    [J]. VALUE IN HEALTH, 2018, 21 : S341 - S341
  • [45] Dimethyl Fumarate: A Review in Relapsing-Remitting MS
    Hannah A. Blair
    [J]. Drugs, 2019, 79 : 1965 - 1976
  • [46] Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study
    Kalincik, T.
    Spelman, T.
    Jokubaitis, V.
    Horakova, D.
    Havrdova, E.
    Izquierdo, G.
    Prat, A.
    Girard, M.
    Duquette, P.
    Lugaresi, A.
    Grammond, P.
    Alroughani, R.
    Lechner-Scott, J.
    Prevost, J.
    Terzi, M.
    Grand'Maison, F.
    Boz, C.
    Trojano, M.
    Van Wijmeersch, B.
    Pucci, E.
    Granella, F.
    Turkoglu, R.
    Sola, P.
    Ferraro, D.
    McCombe, P.
    Solaro, C.
    Van Pesch, V.
    Ozakbas, S.
    Slee, M.
    Spitaleri, D.
    Sanchez-Menoyo, J. L.
    Ampapa, R.
    Hodgkinson, S.
    Karabudak, R.
    Vucic, S.
    Butzkueven, H.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 325 - 327
  • [47] The use of interferon beta in relapsing-remitting multiple sclerosis
    Etheridge, LJ
    Beverley, DW
    Ferrie, C
    McManus, E
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 2004, 89 (08) : 789 - 791
  • [48] Is interferon effective and safe for relapsing-remitting multiple sclerosis?
    Filippini, G
    Incorvaia, B
    [J]. NEUROEPIDEMIOLOGY, 2002, 21 (06) : 310 - 310
  • [49] Safety and efficacy of dimethyl fumarate in a real-world relapsing-remitting multiple sclerosis population
    Barros, A.
    Sequeira, J.
    Sousa, A.
    Capela, C.
    Pedrosa, R.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 877 - 878
  • [50] Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes
    Karl E. Carlström
    Ewoud Ewing
    Mathias Granqvist
    Alexandra Gyllenberg
    Shahin Aeinehband
    Sara Lind Enoksson
    Antonio Checa
    Tejaswi V. S. Badam
    Jesse Huang
    David Gomez-Cabrero
    Mika Gustafsson
    Faiez Al Nimer
    Craig E. Wheelock
    Ingrid Kockum
    Tomas Olsson
    Maja Jagodic
    Fredrik Piehl
    [J]. Nature Communications, 10
12345